Hemodiafiltration and plasma levels of axitinib in a patient with metastatic renal clear cell carcinoma
Background: The standard treatment for metastatic renal cancer is based on vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTor) inhibitors. Compared to other advanced tumors, the treatment of renal cancer is highly affected by impaired renal function; therefore, patient...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Palacký University Olomouc, Faculty of Medicine and Dentistry
2018-11-01
|
| Series: | Biomedical Papers |
| Subjects: | |
| Online Access: | https://biomed.papers.upol.cz/artkey/bio-201804-0014_hemodiafiltration_and_plasma_levels_of_axitinib_in_a_patient_with_metastatic_renal_clear_cell_carcinoma.php |